Literature DB >> 9880581

Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

M Takahashi1, R Terwilliger, C Lane, P S Mezes, M Conti, R S Duman.   

Abstract

The influence of chronic antidepressant administration on expression of the three major phosphodiesterase (PDE) 4 subtypes found in brain (PDE4A, PDE4B, and PDE4D) was examined. The treatments tested included representatives of four major classes of antidepressants: selective reuptake inhibitors of serotonin (sertraline and fluoxetine) or norepinephrine (desipramine), a monoamine oxidase inhibitor (tranylcypromine), and electroconvulsive seizure. Expression of PDE4A and PDE4B, but not PDE4D, mRNA and immunoreactivity were significantly increased in rat frontal cortex by chronic administration of each of the four classes of antidepressants. We also found that antidepressant administration significantly increased the expression of PDE4B mRNA in the nucleus accumbens, a brain region thought to mediate pleasure and reward that could also contribute to the anhedonia often observed in depressed patients. In contrast, expression of PDE4A and PDE4B were not influenced by short-term treatment (1 or 7 d) and were not influenced by chronic administration of nonantidepressant psychotropic drugs (cocaine or haloperidol), demonstrating the time dependence and pharmacological specificity of these effects. Upregulation of PDE4A and PDE4B may represent a compensatory response to antidepressant treatment and activation of the cAMP system. The possibility that targeted inhibition of these PDE4 subtypes may produce an antidepressant effect is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9880581      PMCID: PMC6782198     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene.

Authors:  S L Jin; T Bushnik; L Lan; M Conti
Journal:  J Biol Chem       Date:  1998-07-31       Impact factor: 5.157

Review 2.  Tailoring cAMP-signalling responses through isoform multiplicity.

Authors:  M D Houslay; G Milligan
Journal:  Trends Biochem Sci       Date:  1997-06       Impact factor: 13.807

3.  The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP.

Authors:  J V Swinnen; D R Joseph; M Conti
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 4.  The molecular biology of cyclic nucleotide phosphodiesterases.

Authors:  M Conti; S L Jin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1999

5.  Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain.

Authors:  Y Ye; M Conti; M D Houslay; S M Farooqui; M Chen; J M O'Donnell
Journal:  J Neurochem       Date:  1997-12       Impact factor: 5.372

6.  Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives.

Authors:  D Bobon; M Breulet; M A Gerard-Vandenhove; F Guiot-Goffioul; G Plomteux; M Sastre-y-Hernández; M Schratzer; B Troisfontaines; R von Frenckell; H Wachtel
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

7.  Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase.

Authors:  P Engels; S Abdel'Al; P Hulley; H Lübbert
Journal:  J Neurosci Res       Date:  1995-06-01       Impact factor: 4.164

8.  The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase.

Authors:  C Sette; E Vicini; M Conti
Journal:  J Biol Chem       Date:  1994-07-15       Impact factor: 5.157

9.  Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes.

Authors:  J V Swinnen; D R Joseph; M Conti
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

10.  Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors.

Authors:  H Wachtel; H H Schneider
Journal:  Neuropharmacology       Date:  1986-10       Impact factor: 5.250

View more
  27 in total

1.  Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D.

Authors:  G Hansen; S Jin; D T Umetsu; M Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  [New insights into the pathogenesis and pathophysiology of depression].

Authors:  C Schüle; T C Baghai; R Rupprecht
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 3.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

Review 4.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

5.  Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid.

Authors:  J J Luykx; S C Bakker; E Lentjes; M Neeleman; E Strengman; L Mentink; J DeYoung; S de Jong; J H Sul; E Eskin; K van Eijk; J van Setten; J E Buizer-Voskamp; R M Cantor; A Lu; M van Amerongen; E P A van Dongen; P Keijzers; T Kappen; P Borgdorff; P Bruins; E M Derks; R S Kahn; R A Ophoff
Journal:  Mol Psychiatry       Date:  2013-01-15       Impact factor: 15.992

6.  Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test.

Authors:  Lan Xiao; James P O'Callaghan; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2011-05-12       Impact factor: 4.030

7.  Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.

Authors:  Robbert Havekes; Alan J Park; Rosa E Tolentino; Vibeke M Bruinenberg; Jennifer C Tudor; Yool Lee; Rolf T Hansen; Leonardo A Guercio; Edward Linton; Susana R Neves-Zaph; Peter Meerlo; George S Baillie; Miles D Houslay; Ted Abel
Journal:  J Neurosci       Date:  2016-08-24       Impact factor: 6.167

8.  Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji
Journal:  Curr Psychos Ther Rep       Date:  2006-12

Review 9.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

Authors:  Victoria Boswell-Smith; Domenico Spina
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.